How to Buy Gyre Therapeutics Stock
Gyre Therapeutics Inc
Gyre Therapeutics, Inc. , a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis.
Gyre Therapeutics stock last closed at $9.76, up 1.99% from the previous day, and has decreased 37.44% in one year. It has overperformed other stocks in the Biotechnology industry by 0.39 percentage points. Gyre Therapeutics stock is currently +59.74% from its 52-week low of $6.11, and -48.63% from its 52-week high of $19.00.
At the moment, there are 93.61M shares of GYRE outstanding. The market capitalization of GYRE is $913.66M. In the past 24 hours, 84,234 GYRE shares were traded.
How to Buy Gyre Therapeutics Stock
Wondering how to invest in Gyre Therapeutics stock? Here's how.
- Figure out where to buy Gyre Therapeutics stock: You need to choose an online brokerage, but don't worry - we've analyzed dozens of stock brokerages and apps to help you decide where to buy Gyre Therapeutics stock.
- Sign up for a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Deposit funds into your investment account: Select your method of payment and add your details.
- Research Gyre Therapeutics stock: The Gyre Therapeutics ticker symbol is GYRE. Is Gyre Therapeutics stock a good investment? Should you buy shares of GYRE? How do GYRE's underlying business fundamentals look? Do top analysts think Gyre Therapeutics is a good buy? Why has GYRE's stock price moved recently? (Hint: Our stock market research website can help you figure out if GYRE is a good stock to buy).
- Place your GYRE trade: Decide if you will purchase GYRE shares at the current market price or use a limit order to purchase GYRE stock at a specific price.
- Get key alerts regarding your investment in GYRE: Create a watchlist to key updates about your new investment in Gyre Therapeutics stock.
Step 1: Figure out where to buy Gyre Therapeutics stock
You need a brokerage account to access the NASDAQ market and buy GYRE stock.
Our preferred brokerage: eToro
We believe that eToro is the best online stock brokerage. eToro gives you:
- Invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
- Access to world financial markets: From Tech to Financial Services, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top exchanges.
- Social investing: eToro offers a community with more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your purchase of shares by opening an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Sign up for a brokerage account
Now that you've chosen the best brokerage, you need to fill out some personal info so you are able to buy GYRE stock today.
How to Open a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal data to open your new trading account.
- Send your application by clicking the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your investment account
Now that you have finished signing up on the best stock app for beginners, your next step is to transfer the money for your investment:
Check out the walkthrough below to see the process of transferring funds into your investment account.
Step 4: Research Gyre Therapeutics stock
Once you have decided on the best place to buy Gyre Therapeutics stock, it's very important to evaluate their stock prior to buying, so you actually wrap your head around the risk and upside.
Gyre Therapeutics Numbers
Gyre Therapeutics Overview
WallStreetZen was built to help average investors do better fundamental analysis in minutes instead of hours.
You can view all of the due diligence checks on GYRE's stock page.
How is GYRE stock valued?
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge GYRE's fair value.
Using relative valuations measures:
- GYRE may be undervalued based on its P/E ratio of 69.71x, relative to Biotechnology industry P/E ratio of -162.28x
- GYRE could be overvalued based on its P/B ratio of 14.43x, relative to Biotechnology industry P/B ratio of 4.45x
- GYRE could be undervalued based on its PEG ratio of 0.53x
You can do additional valuation research on GYRE's stock here.
How do GYRE Financials look?
Passed Financial Due Diligence Checks:
- GYRE has cash burn of 5555000. It has enough cash and short-term investments to cover this for at least one year.
- Total GYRE debt is lower than 5 years ago, relative to shareholder equity.
- GYRE profit margin has gone up from -81.9% to 11.4% in the past year.
- There are more short-term assets than long-term liabilities on the GYRE balance sheet.
- There are more short-term assets than short-term liabilities on the GYRE balance sheet.
- GYRE has $31.04M in cash and short term investments. This is sufficient to cover its annual cash burn of $5.56M.
Failed Financial Due Diligence Checks:
- GYRE has a relatively high debt to equity ratio of 0.43.
You can dig deeper into what analysts are saying on the Gyre Therapeutics stock forecast page.
Metrics for Advanced GYRE Traders
GYRE Growth Metrics
Last year, GYRE earnings were $12.09M. Over the past 2 year, GYRE's earnings have increased by 87.08% per year. This was faster than the Biotechnology industry average of 10.4%.
Last year, GYRE revenue was $105.76M. During the last 4 year, GYRE's revenue has gone up by 49.9% per year. This was faster than the Biotechnology industry average of 45.66%.
Find out more about GYRE's earnings and revenue performance here.
Who is buying/selling GYRE?
In the past 12 months, insiders at GYRE have bought more shares than they have sold.
Thomas Wilson Eastling, Director of GYRE, was the latest GYRE insider to buy. They bought $103,950.00 worth of GYRE stock on Apr 16, 2025.
Dig into more about who owns GYRE stock here.
Does GYRE provide a stable income stream?
No, Gyre Therapeutics doesn't provide an income stream by paying out dividends.
What do other traders have to say about GYRE?
One of the primary reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to learn what other investors have to say.
Step 5: Place your GYRE trade
There are two primary options:
- Market order: A market order is an order to buy or sell a stock at the best available price.
Market orders are generally fine for most investors. - Limit order: A limit order enables you to buy or sell a stock at a specific price (or better).
If you want to be certain you're buying or selling at an exact dollar amount limit, use a limit order.
Press the Open Trade button and your broker will place the order.
If you require additional help with investing in stocks on eToro, watch the how to video below:
Step 6: Get key alerts regarding your investment in GYRE
Now that you own some GYRE shares, you'll want to keep up with your new company.
Put GYRE on a watchlist to get notified of the latest news about your GYRE stock.
GYRE Feed
How to Buy Stock in Gyre Therapeutics
To reiterate, here are the 6 steps to buy stock in Gyre Therapeutics:
- Figure out where to buy Gyre Therapeutics stock
- Sign up for a brokerage account
- Deposit funds into your investment account
- Research Gyre Therapeutics stock
- Place your GYRE trade
- Get key alerts regarding your investment in GYRE
If you are looking for a online brokerage, eToro is our recommended venue.
Get Started with eToro TodayIf you would like to keep an eye on your new investment in Gyre Therapeutics, click the button below.
Trending Stock Buying Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.